Stephens & Co. Initiates Coverage On Elevation Oncology With Overweight Rating, Announces Price Target of $8
Stephens & Co. Initiates Coverage On Elevation Oncology With Overweight Rating, Announces Price Target of $8
Stephens & Co.以增持評級啓動Elevation Oncology的保險，宣佈目標股價爲8美元
Stephens & Co. analyst Sudan Loganathan initiates coverage on Elevation Oncology (NASDAQ:ELEV) with a Overweight rating and announces Price Target of $8.
斯蒂芬斯公司分析師蘇丹·洛加納森以增持評級啓動了對Elevation Oncology（納斯達克股票代碼：ELEV）的報道，並宣佈目標股價爲8美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。